INVICTUS
Ripretinib kept fourth-line GIST under control six times longer than placebo and improved survival.
PFS 6.3 vs 1.0 months (HR 0.15); OS 15.1 vs 6.6 months (HR 0.36). Approved May 2020.
- Median 6.3 vs 1 months with Ripretinib compared with Placebo; about 5.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 85 percent lower chance of the event at any given time (hazard ratio 0.15, likely range 0.09 to 0.25).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 15.1 vs 6.6 months with Ripretinib compared with Placebo; about 8.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 64 percent lower chance of the event at any given time (hazard ratio 0.36).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Advanced GIST after ≥3 kinase inhibitors: ripretinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
129 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (median)primary | Ripretinib | 85 | 6.3 months | 0.15 (0.09–0.25) | <0.0001 | link |
| Placebo | 44 | 1 months | ||||
| Overall survival (median) | Ripretinib | — | 15.1 months | 0.36 | — | — |
| Placebo | — | 6.6 months |
Pages like this
not linked directly; found by shared links- PairingctDNA KIT genotyping → TKI selection in GIST
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- TrialINSIGHT
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- CompanyDeciphera Pharmaceuticals (Ono)
- PersonCharles D. Blanke
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPexidartinib
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- TargetPDGFRA
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPazopanib
Shares KIT, Sarcomas (soft tissue, bone, GIST).